Michael Shi

8.9k citations

63 papers · 2.7k indexed · h-index 25

Impact in

Biochemistry top 2%
- Sulfur Compounds in Biology
Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics

Papers in ⓘ

Molecular Biology 33
- Fibroblast Growth Factor Research 10
- Kruppel-like factors research 4
- Redox biology and oxidative stress 3
Oncology 19
- Lung Cancer Research Studies 5

Co-authors: Henry Jay Forman (4 shared papers)Takeo Iwamoto (2 shared papers)Amir Kugelman (2 shared papers)Li Tian (1 shared paper)Peter A. Ward (5 shared papers)Ren-Feng Guo (4 shared papers)Andrea Kay (3 shared papers)Run Liu (1 shared paper)
Journals: Journal of Clinical Oncology (8 papers)Cancer Research (6 papers)Clinical Cancer Research (5 papers)Blood (3 papers)Cancer Immunology Immunotherapy (3 papers)
Partner nations: United States China Switzerland

In The Last Decade

Michael Shi

60 papers receiving 2.6k citations

Peers

Countries citing papers authored by Michael Shi

Since Specialization

Citations

This map shows the geographic impact of Michael Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Shi more than expected).

Fields of papers citing papers by Michael Shi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Shi. The network helps show where Michael Shi may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Shi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Shi Line = papers co-authored together Michael Shi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 63 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Quinone-induced oxidative stress elevates glutathione and induces gamma-glutamylcysteine synthetase activity in rat lung epithelial L2 cells Journal of Biological Chemistry ·Michael Shi, Amir Kugelman, Takeo Iwamoto, Li Tian, Henry Jay Forman	1994	286
2	Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer Clinical Cancer Research ·Fabrice André, Thomas Bachelot, Mario Campone, Florence Dalenc, José Manuel Pérez-García, Sara A. Hurvitz, Nicholas C. Turner, Hope S. Rugo, John W. Smith, Stéphanie Deudon, Michael Shi, Yong Zhang, Andrea Kay, Diana Graus Porta, A. Yovine, José Baselga	2013	251
3	Enabling Large-Scale Pharmacogenetic Studies by High-Throughput Mutation Detection and Genotyping Technologies Clinical Chemistry ·Michael Shi	2001	214
4	γ-Glutamyl Transpeptidase is Increased by Oxidative Stress in Rat Alveolar L2 Epithelial Cells American Journal of Respiratory Cell and Molecular Biology ·Amir Kugelman, Henry A. Choy, Run Liu, Michael Shi, Evelyne Gozal, Henry Jay Forman	1994	142
5	Molecular Cloning and Characterization of DEFCAP-L and -S, Two Isoforms of a Novel Member of the Mammalian Ced-4 Family of Apoptosis Proteins Journal of Biological Chemistry ·Tommy Hlaing, Ren-Feng Guo, Kari A. Dilley, Jennifer M. Loussia, Tammy A. Morrish, Michael Shi, Claudius Vincenz, Peter A. Ward	2001	127
6	Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis Journal of Clinical Investigation ·Ren-Feng Guo, Markus Huber‐Lang, Xin Wang, Vidya Sarma, Vaishalee A. Padgaonkar, Ronald A. Craig, Niels C. Riedemann, Shannon D. McClintock, Tommy Hlaing, Michael Shi, Peter A. Ward	2000	124
7	Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy Clinical Cancer Research ·Michael I. Koukourakis, Alexandra Giatromanolaki, Efthimios Sivridis, Kevin C. Gatter, Tanja Trarbach, Gunnar Folprecht, Michael Shi, David Lebwohl, T. Jalava, Dirk Laurent, Gerold Meinhardt, Adrian L. Harris	2011	115
8	Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma Clinical Cancer Research ·Eric Angevin, José A. López-Martín, Chia‐Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, Daniel Castellano, Jean‐Charles Soria, Paramita Sen, Julie Chang, Michael Shi, Andrea Kay, Bernard Escudier	2013	103
9	Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma Clinical Cancer Research ·Kevin B. Kim, Jason Chesney, Douglas Robinson, Humphrey Gardner, Michael Shi, John M. Kirkwood	2011	100
10	Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis American Journal of Hematology ·Abdullah Kutlar, Julie Kanter, Darla Liles, Ofelia Álvarez, Rodolfo Delfini Cançado, João Ricardo Friedrisch, Jennifer Knight‐Madden, Andreas Bruederle, Michael Shi, Zewen Zhu, Kenneth I. Ataga	2018	88
11	Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy Breast Cancer Research ·Antonino Musolino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos H. Barrios, Javier Cortés, Kimberly Blackwell, Hatem Soliman, Zsuzsanna Kahán, Hervé Bonnefoi, Matthew Squires, Yong Zhang, Stéphanie Deudon, Michael Shi, Fabrice André	2017	87
12	Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma European Journal of Cancer ·Matthew I. Milowsky, Christian Dittrich, Ignacio Durán, Satinder Jagdev, Frederick Millard, Christopher J. Sweeney, Dean F. Bajorin, Linda Cerbone, David I. Quinn, Walter M. Stadler, Jonathan E. Rosenberg, Melissa Lochheed, Paramita Sen, Matthew Squires, Michael Shi, Cora N. Sternberg	2014	82
13	gamma-Glutamylcysteine synthetase and GSH increase in quinone-induced oxidative stress in BPAEC American Journal of Physiology-Lung Cellular and Molecular Physiology ·Michael Shi, Takeo Iwamoto, Henry Jay Forman	1994	81
14	Amino acid variant in the kinase binding domain of dual-specific A kinase-anchoring protein 2: A disease susceptibility polymorphism Proceedings of the National Academy of Sciences ·Stefan Kammerer, Lora Hamuro, Yuliang Ma, Sara Hamon, Jaume M. Cánaves, Michael Shi, Matthew R. Nelson, Charles F. Sing, Charles R. Cantor, Susan S. Taylor, Andreas Braun	2003	80
15	Large-Scale Validation of Single Nucleotide Polymorphisms in Gene Regions Genome Research ·Matthew R. Nelson, George E. Marnellos, Stefan Kammerer, Carolyn R. Hoyal, Michael Shi, Charles R. Cantor, Andreas Braun	2004	80
16	High throughput genotyping for the detection of a single nucleotide polymorphism in NAD(P)H quinone oxidoreductase (DT diaphorase) using TaqMan probes Molecular Pathology ·Michael Shi, Scott P. Myrand, M. R. Bleavins, Felix A. de la Iglesia	1999	71
17	Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells Molecular Cancer Therapeutics ·Gottfried E. Konecny, Teodora Kolarova, Neil A. O’Brien, Boris Winterhoff, Guorong Yang, Jingwei Qi, Zhengdong Qi, Natarajan Venkatesan, Raul Ayala, Tong Luo, Richard S. Finn, Jessica Kristof, Chad Galderisi, Diana Graus Porta, Lee Anderson, Michael Shi, A. Yovine, Dennis J. Slamon	2013	68
18	Serum Lactate Dehydrogenase Levels and Glycolysis Significantly Correlate with Tumor VEGFA and VEGFR Expression in Metastatic Crc Patients Pharmacogenomics ·Mizutomo Azuma, Michael Shi, Kathleen D. Danenberg, Humphrey Gardner, Carl Barrett, Christian Jacques, Andrew Sherod, Syma Iqbal, Anthony B. El-Khoueiry, Dongyun Yang, Wu Zhang, Peter V. Danenberg, Heinz‐Josef Lenz	2007	54
19	Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer Clinical Cancer Research ·Bernard Escudier, Viktor Grünwald, Alain Ravaud, Yen‐Chuan Ou, Daniel Castellano, Chia‐Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, Sarah L Beall, Nicoletta Pirotta, Matthew Squires, Michael Shi, Eric Angevin	2014	49
20	Exogenous glutathione protects endothelial cells from menadione toxicity American Journal of Physiology-Lung Cellular and Molecular Physiology ·M. J. W. Chang, Michael Shi, Henry Jay Forman	1992	47

About Michael Shi

Michael Shi is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Surgery, having authored 63 papers that have together received 2.7k indexed citations. Recurring topics across this work include Fibroblast Growth Factor Research (10 papers), Cancer Genomics and Diagnostics (7 papers), Lung Cancer Treatments and Mutations (7 papers), Renal cell carcinoma treatment (6 papers), Lung Cancer Research Studies (5 papers), Kruppel-like factors research (4 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Redox biology and oxidative stress (3 papers). The work is most often cited by research in Biochemistry (246 citations), Cancer Research (389 citations), Molecular Biology (1.5k citations), Oncology (475 citations) and Immunology (296 citations). Michael Shi has collaborated with scholars based in United States, China and Switzerland. Frequent co-authors include Henry Jay Forman, Takeo Iwamoto, Amir Kugelman, Li Tian, Peter A. Ward, Ren-Feng Guo, Andrea Kay, Run Liu, Henry A. Choy and Evelyne Gozal. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Blood and Cancer Immunology Immunotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact